Short-term outcomes following intra-articular biomaterial injection for pain secondary to stifle osteoarthritis and suspected cranial cruciate ligament injury in dogs.

CEHM intra-articular injection shows feasibility for canine stifle OA/CCD pain based on subjective measures.

This proof-of-concept study evaluated the feasibility and short-term outcomes of intra-articular collagen-elastin hydrogel microparticulate (CEHM) injection in 40 client-owned dogs with suspected cranial cruciate ligament disease (CCD) and/or osteoarthritis (OA). Using Simon's two-stage clinical trial design, dogs received a single CEHM injection with follow-up over 84 days. Primary outcome was improvement in modified Glasgow composite pain score (mGCPS), with 55% of dogs (22/40) achieving ≥25% improvement. Secondary subjective measures including clinician and owner assessments also showed statistically significant improvements. However, the study had significant limitations including lack of objective lameness quantification, surgical confirmation of CCD diagnosis, blinding, randomization, and control group. The CEHM device demonstrated feasibility within subjective pain assessment parameters. The authors acknowledge these methodological constraints and recommend future studies incorporate objective measurements to strengthen evidence. This represents early-stage evaluation of a novel biomaterial approach for canine stifle pathology.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.